Metastatic Prostate Cancer
172
46
72
51
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
24 trials with published results (14%)
Research Maturity
51 completed trials (30% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
8.7%
15 terminated out of 172 trials
77.3%
-9.3% vs benchmark
13%
23 trials in Phase 3/4
47%
24 of 51 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 51 completed trials
Clinical Trials (172)
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
Collection of Blood From Patients With Prostate Cancer
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer